Open Access

Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment

logo

Date: 16 March 2008
Journal: European Heart Journal , Volume 29 , Issue 8 , Pages 1001 - 1010
Authors: P. Karjalainen , S. Vikman , M. Niemelä , P. Porela , A. Ylitalo , M. Vaittinen , M. Puurunen , T. Airaksinen , K. Nyman , T. Vahlberg , K. Airaksinen

ESC Journals

AbstractAims

Uninterrupted anticoagulation (UAC) is assumed to increase bleeding and access-site complications. A common consensus is to postpone percutaneous coronary interventions (PCI) to reach international normalized ratio (INR) levels < 1.5–1.8.

Methods and results

To assess the safety and feasibility of UAC, we analysed retrospectively all consecutive patients (n = 523) on warfarin therapy referred for PCI in four centres with a policy to interrupt anticoagulation (IAC) before PCI and in three centres with a long experience on UAC during PCI. Major bleeding, access-site complications, and major adverse cardiac events (death, myocardial infarction, target vessel revascularization, and stent thrombosis) were recorded during hospitalization. In the IAC group, warfarin was withdrawn for a mean of 3 days prior to PCI (mean INR 1.7). In the UAC group, mean INR value was 2.2. Glycoprotein IIb/IIIa (GP) inhibitors (P < 0.001) and low-molecular-weight heparins (P < 0.001) were more often used in the IAC group. Major bleeding and access-site complications were more common in the IAC group (5.0% vs. 1.2%, P = 0.02 and 11.3% vs. 5.0%, P = 0.01, respectively) than in the UAC group. After adjusting for propensity score, the group difference in access-site complications remained significant [OR (odds ratio) 2.8, 95% CI (confidence interval) 1.3–6.1, P = 0.008], but did not remain significant in major bleeding (OR 3.9, 95% CI 1.0–15.3, P = 0.05). In multivariable analysis, femoral access (OR 9.9, 95% CI 1.3–75.2), use of access-site closure devices (OR 2.1, 95% CI 1.1–4.0), low-molecular-weight heparin (OR 2.7, 95% CI 1.1–6.7) and old age predicted access-site complications, and the use of GP inhibitors (OR 3.0, 95% CI 1.0–9.1) remained as a predictor of major bleeding.

Conclusion

Our study shows that PCI is a safe procedure during UAC with no excess bleeding complications.

About the contributors

Pasi P. Karjalainen

Role: Author

Saila Vikman

Role: Author

Matti Niemelä

Role: Author